GlassScriptPhysician profile
Emily Purdy
NPI 1437600640
$5,469.26
in general payments reported to CMS, 2019-2025
22 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $950 · 2023: $932 · 2024: $1,382 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114 · Education: $88.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,114.37 |
| Education | $88.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,075.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $704.67 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $639.51 | 2023-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $460.72 | 2021-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $411.71 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $359.49 | 2021-2025 | |
| Astellas Pharma US INC | $285.49 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $269.54 | 2021-2023 | |
| Pfizer INC. | $250.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $227.71 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $209.06 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $97.96 | 2025 | |
| Amgen INC. | $74.54 | 2024 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $65.34 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $64.50 | 2025 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $62.61 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $50.41 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $46.67 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.48 | 2022-2025 | Jardiance |
| Sanofi Pasteur INC. | $30.50 | 2022-2025 | |
| Gilead Sciences, INC. | $23.52 | 2025 | |
| Alkermes, INC. | $17.73 | 2025 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Purdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.